Based on this YouTube video's total view count of 323K views and industry-standard rates, the estimated total earning is $227 - $648 through ad revenue. Historical data is not yet available to calculate daily, weekly, or monthly averages.

Explore Vaccination and ivermectin with 323,855 views, 12,492 likes, and 4,836 comments. Experience the impact of this video content that has captured audience attention.

Novavax, 14th June, NVX-CoV2373 https://ir.novavax.com/news-releases/news-release-details/novavax-covid-19-vaccine-demonstrates-90-overall-efficacy-and https://novavax.reportablenews.com/pr/novavax-covid-19-vaccine-19-demonstrates-90-overall-efficacy-and-100-protection-against-moderate-and-severe-disease-in-prevent-19-phase-3-trial Recombinant nanoparticle protein-based COVID-19 vaccine Soapbark tree Influenza and HPV Fridge, 2 doses, 3 week gap Placebo-controlled, double blind, randomized 2:1 100% protection against moderate and severe disease All hospitalizations and deaths in placebo group 90.4% efficacy overall 91% efficacy in high-risk populations (over 65 or comorbidities) N = 29,960, 119 sites, U.S. and Mexico File for regulatory authorizations in the third quarter 100 million doses per month, then 150 million per month by end of 2021 UK, with GlaxoSmithKline, 60 million doses, Barnard Castle Results: Consistent, high efficacy among circulating variants 77 infections Placebo group, 63 Ten moderate cases and four severe Vaccine group, 14 in the vaccine group All cases observed in the vaccine group were mild January 25 through April 30, 2021 Alpha (B.1.1.7) variant, became the predominant strain in the U.S 100% efficacy against variants not considered VoC/Vo Favorable safety profile Generally well-tolerated Serious and severe adverse events few, balanced between vaccine and placebo groups Injection site pain and tenderness, generally mild to moderate, lasting less than 3 days Fatigue, headache and muscle pain, lasting less than 2 days The placebo-controlled portion of PREVENT-19 continues in Adolescents, 12 to 18 years of age Completed enrolment, n = 2,248 Operation Warp Speed, awarded Novavax $1.6 billion contract for 100 million future doses Favorable outcome on viral load and culture viability using Ivermectin in early treatment of non-hospitalized patients with mild COVID-19 – A double-blind, randomized placebo-controlled trial Sheba Medical Center, and Tel Aviv University Ivermectin is an FDA-approved broad spectrum anti-parasitic agent Initially approved in humans in 1987 Nobel prize of Medicine in 2015 With its high safety profile, ivermectin is a potential treatment against COVID-19 in its different stages. https://www.medrxiv.org/content/10.1101/2021.05.31.21258081v1 To assess whether ivermectin can shorten the viral shedding in patients at an early-stage of COVID-19 infection Double blinded randomized control trial Patients receiving ivermectin 0·2 mg/kg for 3 days vs placebo Non-hospitalized COVID-19 patients RT-PCR, recruitment and then every two days Primary endpoint was reduction of viral-load on the 6th day As reflected by Ct level more than 30 (non-infectious level) Primary outcome was supported by determination of viral culture viability Results N = 89 Ivermectin group, 47 Placebo group, 42 Females, 21·6% Asymptomatic at recruitment, 16.8% Symptomatic, 83% On day 6 Ivermectin group 34 out of 47 (72%) reached the endpoint, (non-infectious level) Placebo group 21 out of 42 (50%) reached the endpoint, (non-infectious level) Odds of a negative test at day 6 was 2.62 time higher in the ivermectin group Also Ivermectin group, cultures at days 2 to 6 were positive in 3/23 (13·0%) Placebo group, cultures at days 2 to 6 were positive in 14/29 (48·2%) (p=0·008) 3 hospitalisations, 3 in the placebo group Diarrhoea, 2 and 1 No other adverse effects were reported Conclusions There were significantly lower viral loads and viable cultures in the ivermectin group, which could lead to shortening isolation time in these patients.

With SocialCounts.org’s view counter, track your YouTube video’s live view count and YouTube likes count in real time with fast, reliable updates.

Watch every YouTube video live view count rise with our real-time YouTube views tracker—built for accuracy and minimal delay.

Follow YouTube real time views as they happen, using our dedicated view counter for YouTube videos.

Get up-to-date live view count on YouTube and see real-time growth with SocialCounts.org’s smart tracking tools.